Five-year clinical outcomes of zotarolimus-eluting stents in coronary total occlusions

Henning Kelbæk, Robert W Yeh, Thomas Engstrøm, Franz-Josef Neumann, Patrick W Serruys, Stephan Windecker, Jorge Belardi, Shubin Qiao, Bo Xu, Minglei Liu, Sigmund Silber


AIMS: Reports of long-term outcomes of patients treated with drug-eluting stents in total coronary occlusions are limited. We analyzed clinical outcomes of patients treated with the zotarolimus-eluting Resolute stent (R-ZES) implanted in total coronary versus non-occluded lesions.

METHODS AND RESULTS: Patients treated with R-ZES and included in 4 trials (RESOLUTE All Comers, RESOLUTE International, RESOLUTE China RCT, and RESOLUTE China Registry) were pooled and divided in 3 groups: patients with chronic total occlusions (CTO), patients with total occlusions that had occurred recently (rec-TO), and patients without total occlusions (non-TO). Clinical outcomes at 5-years were analyzed. Of 5,487 patients treated with R-ZES in these trials, 8.0% had CTO's, 8.5% rec-TO's and 83.5% non-TO's. Patients had a mean age of 62.8 years, approximately 25% were female and 30% diabetics. TLF was similar in the 3 groups at 5 years (TLF was 13.2%, 12.5% and 13.3% in the CTO, rec-TO and non-TO groups, respectively, p=0.96). Stent thrombosis tended to occur more frequently for rec-TO compared to CTO and non-TO patients (2.6% vs 1.2% and 1.3%, respectively, p=0.11).

CONCLUSIONS: In this large population of patients who had R-ZES implanted, 5-year clinical outcomes were similar whether or not the stents were implanted in total occlusions.

TidsskriftEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Udgave nummer16
Sider (fra-til)1326-1332
Antal sider7
StatusUdgivet - 19 mar. 2021


Dyk ned i forskningsemnerne om 'Five-year clinical outcomes of zotarolimus-eluting stents in coronary total occlusions'. Sammen danner de et unikt fingeraftryk.